# ES-SCLC combination therapy clinical trial results

> Live situation record from CLSTR: https://clstr.news/situations/es-sclc-combination-therapy-clinical-trial-results
> Updated: 2026-10-26T08:03:04.000Z. Sources: 20. Developments: 2.

Results from the Phase 3 DeLLphi-305 clinical trial indicate that a combination of Amgen’s Imdelltra (tarlatamab) and AstraZeneca’s Imfinzi (durvalumab) significantly improves survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC).

Presented at the ESMO 2026 Congress in Madrid and published in the New England Journal of Medicine, the study found that the combination therapy reduced the risk of death by 58% compared to durvalumab alone. For patients who had not seen disease progression following initial platinum-based chemotherapy, etoposide, and durvalumab, the combination extended median overall survival to 21.1 months, whereas the control group saw 12.7 months. The one-year survival rate for the combination group was approximately 79% to 80%, compared to 53% in the control group.

Regarding safety, approximately 49.6% of patients receiving Imdelltra experienced cytokine release syndrome, though researchers noted these effects are manageable; only one case was reported as serious and none resulted in death. Additionally, severe (Grade 3 and 4) treatment-related adverse events occurred in 20.9% of the combination group.

## Claims

- The combination of Imdelltra and Imfinzi reduced the risk of death by 58% in extensive-stage small cell lung cancer patients. (corroborated by 16 sources)
- Median overall survival for the combination group was 21.1 months. (corroborated by 16 sources)
- Median overall survival for the Imfinzi-only group was 12.7 months. (corroborated by 16 sources)
- Approximately 79% to 80% of patients in the combination group were alive after one year. (corroborated by 16 sources)
- The results were presented at the ESMO 2026 Congress in Madrid. (corroborated by 9 sources)
- Severe (Grade 3 and 4) treatment-related adverse events occurred in 20.9% of the combination group. (single source)
- Approximately 49.6% of patients receiving Imdelltra reported cytokine release syndrome. (single source)
- Imdelltra generated $288 million in sales in Q2, an 115% increase year-on-year. (single source)

## Timeline

### 2026-10-26: New lung cancer therapy reduces death risk by 58%

A Phase III study shows that combining tarlatamab and durvalumab reduces the death risk by 58% for patients with extensive-stage small cell lung cancer.

2 sources. https://clstr.news/cluster/new-lung-cancer-therapy-reduces-death-risk-by-58

### 2026-10-24: Amgen and AstraZeneca drug combo reduces lung cancer death risk by 58%

A Phase 3 trial shows combining Amgen’s Imdelltra with AstraZeneca’s Imfinzi reduces death risk by 58% in extensive-stage small cell lung cancer patients, extending median survival to 21.1 months.

18 sources. https://clstr.news/cluster/amgen-and-astrazeneca-combination-reduces-lung-cancer-death-risk-by-58

---
Cite as: ES-SCLC combination therapy clinical trial results. CLSTR, https://clstr.news/situations/es-sclc-combination-therapy-clinical-trial-results